Nonselective β-blocker propranolol for orbital and periorbital hemangiomas in infants: A new first-line of treatment?

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 1639-1644

  El Essawy, Rania ^a   Galal, Rascha ^a   Abdelbaki, Sameh ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

blockers; Adrenal suppression; Corticosteroids; Orbital and periorbital hemangioma; Propranolol

Indexed keywords

CORTICOSTEROID; PROPRANOLOL;

ARTICLE; CASE STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EYE TUMOR; FEMALE; HEART RATE; HEMANGIOMA; HUMAN; HYPERGLYCEMIA; INFANT; MALE; ONCOLOGICAL PARAMETERS; ORBITAL HEMANGIOMA; PERIORBITAL HEMANGIOMA; PERIPHERAL ISCHEMIA; PROSPECTIVE STUDY; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TUMOR COLOR; TUMOR RECURRENCE; TUMOR TEXTURE; TUMOR VOLUME;

EID: 84856200846     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S24141     Document Type: Article

References (25)

1. Powell J. Update on hemangiomas and vascular malformations. Curr Opin Pediatr. 1999;11(5):457-463.
2. Schwartz SR, Blei F, Ceisler E, Steele M, Furlan L, Kodsi S. Risk factors for amblyopia in children with capillary hemangiomas of the eyelids and orbit. J AAPOS. 2006;10(3):262-368.
3. Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol. 2005;22(5):383-406.
4. Chowdri NA, Darzi MA, Fazili Z, Iqbal S. Intralesional corticosteroid therapy for childhood cutaneous hemangiomas. Ann Plast Surg. 1994; 33(1):46-51.
5. Orawiec B, Stefanczyk L, Czajkowski J, Bogorodzki B. Gralek M. Periorbital capillary hemangiomas in children-treatment and monitoring of treatment. Klin Oczna. 1996;98(3):217-220. Polish.
6. George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140(8):963-969.
7. Cogen MS, Elsas FJ. Eyelid depigmentation following corticosteroid injection for infantile ocular adnexal hemangioma. J Pediatr Ophthalmol Strabismus. 1989;26(1):35-38.
8. Townshend LM, Buckley EG. Linear subcutaneous fat atrophy after a single corticosteroid injection for ocular adnexal hemangioma. Am J Ophthalmol. 1990;109(1):102-103.
9. Sutula FC, Glover AT. Eyelid necrosis following intralesional corticosteroid injection for capillary hemangioma. Ophthalmic Surg. 1987;18(2):103-105.
10. Kushner BJ, Lemke BN. Bilateral retinal embolization associated with intralesional corticosteroid injection for capillary hemangioma of infancy. J Pediatr Ophthalmol Strabismus. 1993;30(6): 397-399.
11. Léauté-Labrèze C, Dumas Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-2651.
12. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998;132(3 Pt 1):527-530.
13. Ritter MR, Butschek RA, Friedlander M, Friedlander SF. Pathogenesis of infantile haemangioma: new molecular and cellular insights. Expert Rev Mol Med. 2007;9(32):1-19.
14. North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile haemangiomas and human placenta. Arch Dermatol. 2001;137(5):559-570.
15. Burton BK, Schulz CJ, Angle B, Burd LI. An increased incidence of hemangiomas in infants born following chorionic villous sampling (CVS). Prenat Diagn. 1995;15(3):209-214.
16. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest. 1994;93(6): 2357-2364.
17. Ritter MR, Reinisch J, Friedlander SF, Friedlander M. Myeloid cells in infantile hemangioma. Am J Pathol. 2006;168(2):621-628.
18. Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1 and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 2005;12(2):409-420.
19. D'Angelo G, Lee H, Weiner RI. CAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem. 1997;67(3):353-366.
20. Annabi B, Lachambre MP, Plouffe K, Moumdjian R, Beliveau R. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res. 2009;60(5):438-445.
21. Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim. 2002; 38(5):298-304.
22. Wiysonge C, Bradley H, Mayosi B, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007;1:CD002003.
23. Chavez H, Ozolins D, Losek JD. Hypoglycemia and propranolol in pediatric behavioral disorders. Pediatrics. 1999;103(6 Pt 1):1290-1292.
24. Abry F, Kehrli P, Speeg-Schatz C. Hemangioma of the eyelids and orbit in children: therapeutic follow-up. J Fr Ophthalmol. 2007;30(2):170-176. French.
25. Chik KK, Luk CK, Chan HB, Tan HY. Use of propranolol in infantile haemangioma among Chinese children. Hong Kong Med J. 2010;16(5):341-346.